Market capitalization | $289.18m |
Enterprise Value | $347.09m |
PER (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 3.85 |
P/S ratio (TTM) P/S ratio | 3.21 |
P/B ratio (TTM) P/B ratio | 7.11 |
Sales growth (TTM) Sales growth | 61.75% |
Turnover (TTM) Turnover | $90.22m |
As a free StocksGuide basic user, you can view the scores for all 6,953 shares worldwide.
4 Analysts have issued a Alimera Sciences, Inc. forecast:
4 Analysts have issued a Alimera Sciences, Inc. forecast:
Mar '24 | |
Current assets | 54 54 |
Fixed assets | 98 98 |
Total assets | 152 152 |
Mar '24 | |
Equity | 41 41 |
Debt capital | 112 112 |
Total capital | 152 152 |
Figures in millions USD.
If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.
Alimera Sciences, Inc. engages in the research and development of biopharmaceutical products. It operates through the U.S. and International geographic segments. The firm focuses on the development of ophthalmic pharmaceuticals for the treatment of diabetic macular edema, wet and dry age-related macular degeneration, and retinal vein occlusion. Its products include ILUVIEN and NADPH Oxidase Inhibitors. The company was founded by Daniel C. Myers and David R. Holland on June 4, 2003 and is headquartered in Alpharetta, GA.
Head office | United States |
CEO | Richard Eiswirth |
Employees | 159 |
Founded | 2003 |
Website | www.alimerasciences.com |
StocksGuide is the tool for easily finding, analyzing and monitoring shares. Learn from successful investors and make well-founded investment decisions. We make you a self-determined investor.